Overview

Signaling Mechanisms and Vascular Function in Diabetes Mellitus

Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
Ruboxistaurin is being tested to see if it is effective in treating certain diabetic complications, such as diseases of the blood vessels.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborator:
Eli Lilly and Company
Treatments:
Ruboxistaurin